Psoriasis News and Research RSS Feed - Psoriasis News and Research

Psoriasis is a chronic, immune-mediated disease that results from the overproduction of skin cells, resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that approximately 7.5 million Americans and nearly 3 percent of the world's population are living with psoriasis and nearly one-quarter of those people have cases that are considered moderate to severe.
Some genetic features associated with modern diseases are ancient

Some genetic features associated with modern diseases are ancient

Psoriasis, a chronic skin condition, can cause rashes that itch and sting. So why would a genetic susceptibility to this and other ailments persist for hundreds of thousands of years, afflicting our ancient ancestors, and us? [More]
Scientists take a huge step forward in identifying root causes of psoriasis

Scientists take a huge step forward in identifying root causes of psoriasis

Case Western Reserve scientists have taken a huge leap toward identifying root causes of psoriasis, an inflammatory skin condition affecting 125 million people around the world. Of the roughly 50,000 proteins in the human body, researchers have zeroed in on four that appear most likely to contribute this chronic disease. [More]
Kinex Pharmaceuticals doses first actinic keratosis patient with KX2-391 ointment

Kinex Pharmaceuticals doses first actinic keratosis patient with KX2-391 ointment

Kinex Pharmaceuticals announced today that the first actinic keratosis patient has been dosed with KX2-391 ointment in Austin, Texas. [More]
Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. [More]
3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea. [More]
Study finds difference between results from IHC and quantitative molecular techniques

Study finds difference between results from IHC and quantitative molecular techniques

The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes. [More]
Some medicines can make skin sun-sensitive, says NPS MedicineWise clinical adviser

Some medicines can make skin sun-sensitive, says NPS MedicineWise clinical adviser

Some medicines can make your skin more sensitive to the sun and this summer season NPS MedicineWise advises Australians to check their medicines packaging for warnings to avoid excessive skin exposure to sunlight and sunlamps. [More]
LEO Pharma submits NDA for aerosol foam formulation to treat patients with plaque psoriasis

LEO Pharma submits NDA for aerosol foam formulation to treat patients with plaque psoriasis

LEO Pharma announces it has submitted a New Drug Application (NDA) for calcipotriene and betamethasone dipropionate aerosol foam, 0.005%/0.064%, to the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis. [More]
Fat cells below skin help protect from bacteria, say researchers

Fat cells below skin help protect from bacteria, say researchers

When it comes to skin infections, a healthy and robust immune response may depend greatly upon what lies beneath. In a new paper published in the January 2, 2015 issue of Science, researchers at the University of California, San Diego School of Medicine report the surprising discovery that fat cells below the skin help protect us from bacteria. [More]
Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it completed the design of the Rheumatoid Arthritis (RA) Phase III study of its lead drug candidate CF101. [More]
Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
Researchers identify a single protein as root cause of multiple allergic reactions

Researchers identify a single protein as root cause of multiple allergic reactions

Johns Hopkins and University of Alberta researchers have identified a single protein as the root of painful and dangerous allergic reactions to a range of medications and other substances. If a new drug can be found that targets the problematic protein, they say, it could help smooth treatment for patients with conditions ranging from prostate cancer to diabetes to HIV [More]
Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies. [More]
Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Eli Lilly and Company and Incyte Corporation today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment. [More]
Researchers gain new insights into potential treatment for Alzheimer's disease

Researchers gain new insights into potential treatment for Alzheimer's disease

It is estimated that about 35 million people worldwide currently suffer from dementia and it is expected that the number will increase to 135 million by the year 2050. The disease is already one of the most common health problems in the elderly, which is why experts predict that the numbers of people affected will increase over time. [More]
Oncologists examine efficacy of rose bengal against cancer

Oncologists examine efficacy of rose bengal against cancer

Rose Bengal has been around for decades starting as a way to dye wool. Originally used in medicine as a stain for ophthalmologists, it has a solid safety record going back to the 1930s. Recently, oncologists have examined its efficacy against cancer, specifically melanoma. [More]
Abnormal activation of cell death pathways may lead to inflammatory skin diseases

Abnormal activation of cell death pathways may lead to inflammatory skin diseases

Inflammatory skin diseases such as psoriasis may result from abnormal activation of cell death pathways previously believed to suppress inflammation, a surprise finding that could help to develop new ways of treating these diseases. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
Study points to major role of obesity in triggering, prolonging autoimmune diseases

Study points to major role of obesity in triggering, prolonging autoimmune diseases

Autoimmune diseases like Crohn's Disease and multiple sclerosis, in which the immune system attacks its own body rather than predatory invaders, affect 5-20% of the global community. A study published recently in Autoimmunity Reviews by Prof. Yehuda Shoenfeld, the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases at Tel Aviv University's Sackler Faculty of Medicine and Head of Zabludowicz Center for Autoimmune Diseases at Chaim Sheba Medical Center, Tel Hashomer, points to the major role obesity plays in triggering and prolonging these autoimmune diseases. [More]
National Psoriasis Foundation to hold free psoriatic arthritis program in Dallas-Fort Worth area

National Psoriasis Foundation to hold free psoriatic arthritis program in Dallas-Fort Worth area

If you're one of the roughly 48,000 Dallas-Fort Worth area residents struggling with pain from psoriatic arthritis (PsA)—an inflammatory autoimmune disease that causes pain, swelling and stiffness of the joints and tendons—learn to control your condition with Be Joint Smart, a free psoriatic arthritis program presented by the National Psoriasis Foundation, at the Dallas Marriott Las Colinas on December 6. [More]